ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 579

Is There an Impact of Uveitis, Psoriasis and Inflammatory Bowel Disease on Musculoskeletal Disease Activity and Function in Axial Spondyloarthritis?

Imke Redeker1, Johanna Callhoff 2, Falk Hoffmann 3, Hildrun Haibel 4, Joachim Sieper 4, Angela Zink 5 and Denis Poddubnyy 6, 1Charité – Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, 2German Rheumatism Research Centre, Berlin, Germany, 3Carl von Ossietzky University, Oldenburg, Germany, 4Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, 5German Rheumatism Research Centre and Charité University medicine, Berlin, Germany, 6Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: axial spondyloarthritis, inflammatory bowel disease (IBD), psoriasis and Disease Activity, Uveitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Uveitis, psoriasis and inflammatory bowel disease (IBD) are common in axial spondyloarthritis (axSpA) but data on their impact on activity of musculoskeletal manifestations and functional status, in general, are contradictory. The aim of this study was to assess the impact of uveitis, psoriasis, and IBD on disease activity and functional status in a population-based cohort of patients with axSpA.

Methods: A stratified random sample of patients with axSpA (ICD-10 M45) was drawn from health insurance data in Germany. Patients in the sample received a survey on demographic, socioeconomic, and disease-related parameters including history of uveitis, psoriasis, and IBD.

Survey data were linked to health insurance data gathering additional information on recent/current occurrence (within one year) of uveitis, psoriasis, and IBD as well as drug prescriptions and non-pharmacological treatment.

Differences between patients with and without uveitis, psoriasis, and IBD were assessed. Separate multivariable linear regression models were calculated to determine the effect of uveitis, psoriasis, and IBD on disease activity and functional impairment after adjustment for other relevant parameters including treatment.

Results: A total of 1,729 patients with axSpA were included in the analyses. The patients’ main characteristics are shown in Table 1: The mean age was 55.9 years and 46.1% were female. The prevalence for recent (ever) uveitis, psoriasis, and IBD is illustrated in Figure: 9% (27%) of the patients had recently (ever) uveitis, 10% (15%) had recently (ever) psoriasis, and 6% (9%) had recently (ever) IBD. In 1.6% (6.9%) of the patients two of these conditions were recently (ever) present, and in 0% (0.5%) of the patients, all three conditions were recently (ever) present.

Results from the multivariable linear regression analyses are presented in Table 2 and revealed that history of psoriasis was significantly associated with both higher level of disease activity and higher level of functional impairment. History of IBD was also associated with higher disease activity, whereas recent psoriasis or IBD showed no strong association with disease activity and functional status.

In contrast, history of uveitis showed no strong association with disease activity and functional status while recent uveitis was significantly associated with lower disease activity according to the BASDAI even after adjustment for treatment.

Conclusion: Disease activity and functional impairment are higher in axSpA patients with a history of psoriasis or IBD, whereas history of uveitis does not have a major impact on activity of musculoskeletal manifestations and functional status in axSpA. However, recent uveitis showed a somewhat unexpected association with lower disease activity. The latter might be related to a higher likelihood of being treated with TNF inhibitors in the presence of uveitis.


Disclosure: I. Redeker, None; J. Callhoff, None; F. Hoffmann, None; H. Haibel, AbbVie, 5, 8, Janssen, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8; J. Sieper, AbbVie, 5, 8, Eli Lilly and Company, 5, 8, Janssen, 5, 8, Lilly, 5, 8, Merck, 5, 8, Novartis, 5, 8; A. Zink, Astra Zeneca, BMS, Lilly, Pfizer, Roche und UCB, 5, 8; D. Poddubnyy, Abbvie, 2, 5, 8, AbbVie, 2, 5, 8, BMS, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Eli Lilly and Company, 2, 5, 8, Lilly, 5, 8, MSD, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Roche, 5, 8, UCB, 5, 8.

To cite this abstract in AMA style:

Redeker I, Callhoff J, Hoffmann F, Haibel H, Sieper J, Zink A, Poddubnyy D. Is There an Impact of Uveitis, Psoriasis and Inflammatory Bowel Disease on Musculoskeletal Disease Activity and Function in Axial Spondyloarthritis? [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/is-there-an-impact-of-uveitis-psoriasis-and-inflammatory-bowel-disease-on-musculoskeletal-disease-activity-and-function-in-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-there-an-impact-of-uveitis-psoriasis-and-inflammatory-bowel-disease-on-musculoskeletal-disease-activity-and-function-in-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology